Outset Medical (NASDAQ:OM) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Outset Medical (NASDAQ:OM) from a sell rating to a hold rating in a research note issued to investors on Saturday.

OM has been the subject of several other research reports. TD Cowen restated a “buy” rating on shares of Outset Medical in a research report on Friday, May 8th. Weiss Ratings upgraded shares of Outset Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 7th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $10.00.

Outset Medical Price Performance

Shares of NASDAQ OM opened at $4.51 on Friday. Outset Medical has a 1-year low of $3.00 and a 1-year high of $16.16. The business has a 50-day moving average of $4.58 and a 200-day moving average of $4.25. The company has a debt-to-equity ratio of 1.03, a current ratio of 5.19 and a quick ratio of 4.97. The company has a market capitalization of $84.79 million, a price-to-earnings ratio of -1.10 and a beta of 1.96.

Outset Medical (NASDAQ:OM) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.08). The business had revenue of $31.64 million during the quarter, compared to analysts’ expectations of $28.97 million. Outset Medical had a negative net margin of 63.06% and a negative return on equity of 61.67%. On average, equities analysts anticipate that Outset Medical will post -3.9 EPS for the current fiscal year.

Insiders Place Their Bets

In other Outset Medical news, CFO Renee Gaeta sold 17,672 shares of Outset Medical stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $4.94, for a total transaction of $87,299.68. Following the transaction, the chief financial officer directly owned 113,753 shares in the company, valued at approximately $561,939.82. The trade was a 13.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Legal & General Group Plc bought a new position in shares of Outset Medical in the second quarter valued at approximately $34,000. BNP Paribas Financial Markets increased its stake in shares of Outset Medical by 7,013.8% in the second quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock worth $40,000 after purchasing an additional 2,034 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Outset Medical by 4.1% in the first quarter. Bank of New York Mellon Corp now owns 62,360 shares of the company’s stock worth $239,000 after purchasing an additional 2,435 shares during the period. Geode Capital Management LLC boosted its stake in Outset Medical by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 400,363 shares of the company’s stock valued at $1,486,000 after purchasing an additional 3,104 shares during the period. Finally, Barclays PLC grew its holdings in Outset Medical by 9.8% in the 4th quarter. Barclays PLC now owns 37,682 shares of the company’s stock valued at $140,000 after buying an additional 3,356 shares during the last quarter.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.